Form 8-K - Current report:
SEC Accession No. 0001193125-25-268056
Filing Date
2025-11-06
Accepted
2025-11-06 07:10:25
Documents
12
Period of Report
2025-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-20251106.htm   iXBRL 8-K 55192
2 EX-99.1 achv-ex99_1.htm EX-99.1 291142
3 GRAPHIC img9551541_0.jpg GRAPHIC 21022
  Complete submission text file 0001193125-25-268056.txt   536866

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20251106.xsd EX-101.SCH 51387
14 EXTRACTED XBRL INSTANCE DOCUMENT achv-20251106_htm.xml XML 6342
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 251456116
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)